Navigation Links
Pharmos Completes Private Placement - Raises $1.8 Million
Date:4/21/2009

ISELIN, N.J., April 21 /PRNewswire-FirstCall/ -- Pharmos Corporation (Pink Sheets: PARS) announced today that it has completed a private placement of common stock and warrants. At the closing, the Company issued 18,000,000 shares of common stock and warrants exercisable for an additional 18,000,000 shares of common stock for an aggregate purchase price of $1,800,000. The exercise price of the warrants, which have a five-year term, is $0.12 per share.

The three purchasers were two existing investors in the Company, Venrock Associates (which is affiliated with Anthony B. Evnin, a Director of the Company) and New Enterprise Associates (which is affiliated with Charles W. Newhall, III, a Director of the Company), and a trust affiliated with Robert F. Johnston (the Company's Executive Chairman of the Board of Directors). With respect to the private placement of the securities sold, the Company relied on the exemption from registration under the Securities Act of 1933, as amended (the "Act") provided by Rule 506 under the Act, given the number of, and nature of, the investors.

In addition, Venrock Associates, New Enterprise Associates and Mr. Johnston agreed to convert at the closing the Company's 10% Convertible Debentures due November 1, 2012 held by them, comprising an aggregate of $3,000,000 in principal amount, at a conversion price of $0.275 per share. Accrued but unpaid interest on their debentures, aggregating $80,403, was also converted at the closing, at a conversion price of $0.34 per share. An aggregate of 11,145,569 shares was issued at the closing upon conversion of the principal and accrued but unpaid interest on the debentures.

The proceeds from the private placement will be used to fund completion of the ongoing Dextofisopam Phase 2b trial and company operations through 2009. If the trial is successful, this financing would also support additional efforts to negotiate a strategic partnership or license arrangement with a pharmaceutical company. This is consistent with Pharmos' strategy as previously communicated, since the Company does not have the resources to continue to develop Dextofisopam through a Phase 3 trial.

About Pharmos Corporation

Pharmos discovers and develops novel therapeutics to treat a range of indications including specific diseases of the nervous system such as disorders of the brain-gut axis (IBS), pain/inflammation, and autoimmune disorders. The Company's lead product in development, Dextofisopam, is undergoing Phase 2b testing in IBS patients. Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders. These are available for licensing / partnering. On February 18, 2009, Pharmos Corporation and its Israeli subsidiary, Pharmos Ltd., entered into an Asset Purchase Agreement with Reperio Pharmaceuticals Ltd. for the sale of the patent rights and technical know-how related to the compound known as PRS-639,058 and certain follow-on molecules.

Safe Harbor Statement

Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.


'/>"/>
SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmos Restructures Operations in Israel
2. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
3. Pharmos Corporation Reports 2008 Third Quarter Results
4. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
5. Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved
6. Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
7. Eligard(R) six-month formulation successfully completes European approval procedure
8. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
9. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
10. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
11. GSI Securitization Completes Merger and Domicile Transfer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ... and eliminate cyber threats in real-time, today announced a strategic partnership with ... customers to monitor, respond and protect their critical information assets and infrastructure, in ...
(Date:1/24/2017)... ... 24, 2017 , ... His message has been heard by more than 100,000 ... Distracted Driving , Joel Feldman, has reached his biggest national audience yet: the three ... the top newspapers in circulation in the country, and he hopes it will help ...
(Date:1/24/2017)... ... ... Saturday, January 28, the BCFA presents more than 20 local performances including Chinese music, ... Zhou, Mara McClain & Sarah Nordlund Dennis. Local chefs and restaurants provide a taste ... games, crafts & more. Festivities begin at 11:00 am and end at 2:30 pm. ...
(Date:1/24/2017)... ... January 24, 2017 , ... Inspiration, Community ... Well-meaning studies such as the Fordham Institute’s High Stakes for High Achievers ... such as including gifted or high-achieving students as a subgroup and reporting their ...
(Date:1/24/2017)... ... January 24, 2017 , ... Date aired: January ... Sharon Kleyne, the nation’s foremost water advocate and host of the nationally syndicated ... on Voice America, once again welcomed one of her favorite guests and colleagues, ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... India , January 24, 2017 ... titled, "Cold Chain Logistics Market by Application Type (Fruits ... Meat, Fish & Sea Food, Drugs & Pharmaceuticals, and ... projects that the global cold chain logistics market is ... a CAGR of 16% (2016 to 2022). ...
(Date:1/24/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and ... finalists in the Regeneron Science Talent Search, the nation,s ... high school seniors. Finalists were selected based on the ... The finalists will now go to ... undergo a rigorous judging process to determine the top ...
(Date:1/24/2017)... 24, 2017 Research and Markets has announced ... Trends - Product, Material - Forecast to 2025" report to ... ... a CAGR of around 5.4% over the next decade to reach ... trends that the market is witnessing include 3D medical printing is ...
Breaking Medicine Technology: